Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426359 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
A Phase 2 study, sponsored by Qurient Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT02426359 is a Phase 2 study that has completed, run by Qurient Co.. The registered enrollment target is 57 participants.
The verdict
NCT02426359, a Phase 2 study, has completed, sponsored by Qurient Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
Interventions
- DRUG Placebo
- DRUG Q301 Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02426359
The ClinicalTrials.gov registry entry for NCT02426359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qurient Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02426359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02426359 about?
NCT02426359 is a clinical study titled "Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients". This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.
What is the current status of trial NCT02426359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2015-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02426359?
The interventions under investigation include: Placebo (DRUG), Q301 Cream (DRUG).
Who is sponsoring clinical trial NCT02426359?
This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.